GBC expands its business portfolio by investing in StemCyte Inc., a global leader in cord blood therapeutics that offers public and private cord blood banking.
2002
GBC is listed on the Taiwan Emerging Stock Board (4117).
2004
ISO-13485 Certified.
2008
Real-Time PCR first product launch.
Knowing someone has hepatitis B is not enough — doctors need to know the viral load in order to correctly treat and monitor the condition. To this end, we launch our first GB HBV RealQuant PCR Kit.
2012
Innovation continues.
With Liver Fibrosis a critical part of liver disease that clinical doctors needed to identify, we started working with ITRI (Industrial Technology Research Institute of Taiwan). As a result, BioFibroScore® is born.